The stock of iSpecimen Inc (ISPC) has seen a -7.16% decrease in the past week, with a 11.00% gain in the past month, and a -26.87% decrease in the past quarter. The volatility ratio for the week is 10.45%, and the volatility levels for the past 30 days are at 18.37% for ISPC. The simple moving average for the past 20 days is -2.47% for ISPC’s stock, with a -24.12% simple moving average for the past 200 days.
Is It Worth Investing in iSpecimen Inc (NASDAQ: ISPC) Right Now?
Moreover, the 36-month beta value for ISPC is 1.59. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ISPC is 0.80M and currently, short sellers hold a 5.15% of that float. On November 15, 2024, ISPC’s average trading volume was 404.32K shares.
ISPC) stock’s latest price update
iSpecimen Inc (NASDAQ: ISPC)’s stock price has plunge by 4.37relation to previous closing price of 4.35. Nevertheless, the company has seen a -7.16% plunge in its stock price over the last five trading sessions. newsfilecorp.com reported 2024-11-08 that Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts–(Newsfile Corp. – November 8, 2024) – iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.
ISPC Trading at -3.24% from the 50-Day Moving Average
After a stumble in the market that brought ISPC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.95% of loss for the given period.
Volatility was left at 18.37%, however, over the last 30 days, the volatility rate increased by 10.45%, as shares sank -1.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.79% lower at present.
During the last 5 trading sessions, ISPC fell by -7.69%, which changed the moving average for the period of 200-days by -52.00% in comparison to the 20-day moving average, which settled at $4.65. In addition, iSpecimen Inc saw -54.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ISPC
Current profitability levels for the company are sitting at:
- -0.94 for the present operating margin
- 0.31 for the gross margin
The net margin for iSpecimen Inc stands at -0.92. The total capital return value is set at -1.95. Equity return is now at value -109.34, with -69.12 for asset returns.
Based on iSpecimen Inc (ISPC), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -13.42. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -469.86.
Currently, EBITDA for the company is -9.1 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 0.29. The receivables turnover for the company is 6.28for trailing twelve months and the total asset turnover is 0.92. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To wrap up, the performance of iSpecimen Inc (ISPC) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
